Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Down 37.9% in October

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large decline in short interest in October. As of October 31st, there was short interest totalling 350,900 shares, a decline of 37.9% from the October 15th total of 565,500 shares. Approximately 7.6% of the company’s stock are sold short. Based on an average trading volume of 281,500 shares, the short-interest ratio is currently 1.2 days.

Virpax Pharmaceuticals Price Performance

Shares of NASDAQ VRPX traded down $0.02 during midday trading on Friday, hitting $0.62. 73,321 shares of the company’s stock were exchanged, compared to its average volume of 1,798,571. The firm’s fifty day simple moving average is $0.67 and its 200-day simple moving average is $0.96. Virpax Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $8.00.

Virpax Pharmaceuticals (NASDAQ:VRPX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($1.75) earnings per share for the quarter.

Institutional Investors Weigh In On Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new stake in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 32.23% of the company’s stock.

Analysts Set New Price Targets

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.